Dorman Products (DORM) Falls Short of Q2 Views
Tweet
Share
E-mailGet Alerts DORM Hot Sheet
Join SI Premium – FREE
Dorman Products (NASDAQ: DORM) reported Q2 EPS of $0.70, $0.04 worse than the analyst estimate of $0.74. Revenue for the quarter came in at $131.6 million versus the consensus estimate of $133.84 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freedom Broker Downgrades Dorman Products (DORM) to Hold
- Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
- CaliberCos Inc (CWD) Misses Q2 EPS by 43c; Offers Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
